ReviewClinical immunology (Orlando, Fla.)2011
Targeting iNKT cells for the treatment of sickle cell disease.
Review in Clinical immunology (Orlando, Fla.), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 48 citations in OpenAlex.
- IL-15 protects NKT cells from inhibition by tumor-associated macrophages and enhances antimetastatic activity.The Journal of clinical investigation · 2012Trial
- Sickle cell disease (SCD), iNKT cells, and regadenoson infusion.Transactions of the American Clinical and Climatological Association · 2012Trial
- invariant Natural Killer T cell therapy as a novel therapeutic approach in hematological malignancies.Frontiers in transplantation · 2024Review
- Harnessing invariant natural killer T cells to control pathological inflammation.Frontiers in immunology · 2022Review
- Emerging disease-modifying therapies for sickle cell disease.Haematologica · 2019Review
- Characterization of natural killer cells expressing markers associated with maturity and cytotoxicity in children and young adults with sickle cell disease.Pediatric blood & cancer · 2019Article
- Editorial: Role of CD1- and MR1-Restricted T Cells in Immunity and Disease.Frontiers in immunology · 2019Article
- Application of phospho-CyTOF to characterize immune activation in patients with sickle cell disease in an ex vivo model of thrombosis.Journal of immunological methods · 2018Article
- Developing new pharmacotherapeutic approaches to treating sickle-cell disease.ISBT science series · 2017Article
- Emerging point-of-care technologies for sickle cell disease screening and monitoring.Expert review of medical devices · 2016Review
- Are human iNKT cells keeping tabs on lipidome perturbations triggered by oxidative stress in the blood?Immunogenetics · 2016Review
- Sickle cell disease biochip: a functional red blood cell adhesion assay for monitoring sickle cell disease.Translational research : the journal of laboratory and clinical medicine · 2016Article
- Neutrophils, platelets, and inflammatory pathways at the nexus of sickle cell disease pathophysiology.Blood · 2016Review
- Review
- Beneficial and detrimental role of adenosine signaling in diseases and therapy.Journal of applied physiology (Bethesda, Md. : 1985) · 2015Review
- Triterpenoid inducers of Nrf2 signaling as potential therapeutic agents in sickle cell disease: a review.Frontiers of medicine · 2015Review
- Mouse Invariant Monoclonal Antibody NKT14: A Novel Tool to Manipulate iNKT Cell Function In Vivo.PloS one · 2015Article
- Biomarkers and recent advances in the management and therapy of sickle cell disease.F1000Research · 2015Review
- Advances in sickle cell therapies in the hydroxyurea era.Molecular medicine (Cambridge, Mass.) · 2014Review
- Different subsets of natural killer T cells may vary in their roles in health and disease.Immunology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
Abstract
Sickle cell disease (SCD) causes widely disseminated vaso-occlusive episodes. Building on evidence implicating invariant NKT (iNKT) cells in the pathogenesis of ischemia/reperfusion injury, recent studies demonstrate that blockade of iNKT cell activation in mice with SCD reduces pulmonary inflammation and injury. In patients with SCD, iNKT cells in blood are increased in absolute number and activated in comparison to healthy controls. iNKT cell activation is reduced by agonists of adenosine 2A receptors (A(2A)Rs) such as the clinically approved coronary vasodilator, regadenoson. An ongoing multi-center, dose-finding and safety trial of infused regadenoson, has been initiated and is providing preliminary data about its safety and efficacy to treat SCD. Very high accumulation of adenosine may have deleterious effects in SCD through activation of adenosine 2B receptors that are insensitive to regadenoson. Future possible therapeutic approaches for treating SCD include selective A(2B)R antagonists and antibodies that deplete iNKT cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.